Riskpilot← Back to searchSign inGet full accessGudna Pharma AB
ABActiveOrg 5592207657Erik Dahlbergsgatan 11 A Vån 2Research and experimental development on natural sciences and engineering · NACE 7210Est. 20190 employees
Revenue 2024
SEK 0
EBITDA margin
—
-12% vs 2023
Equity ratio
92.3%
Financial strength
Net profit 2024
SEK -28K
-17% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -27K | -12% |
| Net profit | SEK -28K | -17% |
| Total assets | SEK 517K | +0% |
| Equity | SEK 477K | -6% |
| Employees | 0 | — |
Legal name
Gudna Pharma AB
Org number
5592207657
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
1 oktober 2019
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget skall bedriva forskning och samt kommersiell utveckling syftande till kommersiell exploatering av läkemedel för svåra degenerativa sjukdomar. Inom området degenerativa sjukdomar skall bolaget även direkt eller indirekt bedriva investeringsverksamhet och i samband därmed förvärva, äga och förvalta samt försälja andelar, aktier, delrätter och andra värdepapper samt förvärva rättigheter och ikläda sig skyldigheter i samband med investeringar i eller saminvesteringar med bolag eller fonder samt därmed förenlig verksamhet.
Address
Erik Dahlbergsgatan 11 A Vån 2
Email
klementina@ventures.gu.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −25 | −33 | −19 | −24 | −27 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | −25 | −33 | −19 | −24 | −27 |
| Net financials | — | −10 | 10 | — | −1 |
| Profit before tax | −25 | −43 | −9 | −24 | −28 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −25 | −43 | −9 | −24 | −28 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 531 | 498 | 508 | 515 | 517 |
| Equity | 531 | 489 | 500 | 505 | 477 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 0 | 9 | 8 | 10 | 40 |
| Total debt | — | 9 | 8 | 10 | 40 |
EBITDA margin
-2700000.0%
This company
15.8%
Market median
-17088708% vs market
20202024
Equity ratio
92.3%
This company
38.2%
Market median
+142% vs market
20202024
Return on equity
-5.9%
This company
18.4%
Market median
-132% vs market
20202024
Net profit margin
-2800000.0%
This company
8.1%
Market median
-34568001% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
0.08×
This company
0.62×
Market median
+87% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2019-10-01 – 2020-12-31
No data on file.
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2022 | — | — | |
| Deputy Board Member | 2023 | — | — | |
| Deputy Board Member | 2022 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
GU Ventures AB | Company | 100.0% | 100.0% | 0001 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
GÖTEBORGS UNIVERSITET
Gudna Pharma AB Board members of Gudna Pharma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Klementina Österberg | Board of Directors | 0 companies |
| Per Jesper Dahlberg | Deputy Board Member | 0 companies |
| Bengt Anders Waas | Deputy Board Member | 0 companies |